Vanguard reports 4.51M Veracyte shares (5.67%)
Veracyte Inc reported beneficial ownership by Vanguard Portfolio Management LLC.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Veracyte Inc reported beneficial ownership by Vanguard Portfolio Management LLC. Vanguard Portfolio Management beneficially owns 4,512,852 shares of Veracyte common stock, representing 5.67% of the class. The filing shows 68,122 shares with sole voting power and 4,512,852 shares with sole dispositive power. The filing is signed by Ashley Grim on 04/29/2026.
Key Figures
Key Terms
Schedule 13G regulatory
beneficially owned financial
sole dispositive power regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of Veracyte does Vanguard Portfolio Management own according to the filing?
Who signed the Schedule 13G filing for Vanguard and when was it signed?
AI-generated analysis. How Rhea-AI works. Not financial advice.